Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

April 24 (Reuters) - Bristol-Myers Squibb and Pfizer said on Friday they will start selling their jointly developed blood ...

Pfizer has a higher-yielding dividend, but it may not be safe. AbbVie has the better path to growth in 2026. But when you ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term ...

The latest trading day saw Pfizer (PFE) settling at $26.8, representing a -1.87% change from its previous close.

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

Pfizer (PFE) stock is in focus as executive Andrew Baum, who joined the company in 2024 as the Chief Strategy and Innovation ...

We just covered the 15 Safe Stocks to Invest In For Beginners and Pfizer Inc. (NYSE:PFE) ranks 14th on this list. Pfizer Inc.

April 20 (Reuters) - Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will ...